America’s most powerful medtech trade organization, AdvaMed, is asking the Trump Administration for immunity from tariffs on Canada, China, and Mexico. Like many other industries, the medical technology sector is in danger of being caught in the crossfire of tariff wars triggered by President Donald Trump’s recent executive orders.

ODT’s editorial board members looked back at 2024 and shared their thoughts on what the industry could expect in 2025. Marc Mackey, senior VP & GM of Enabling Technologies at Enovis, and Melanie Prevost, associate director of ASC Solutions at Zimmer Biomet, provided feedback.

Gyder Surgical has gained U.S. FDA 510(k) clearance for its GYDER Hip System, touted as the world’s first commercially available non-invasive (pinless), image-less solution for accurate acetabular cup positioning during anterior hip arthroplasty.

In partnership with the University of Florida, Evergen launched a new AI-powered bone graft image processing software, which streamlines tissue processing by analyzing data from CT scans of human bone grafts.

BIOTRONIK Neuro announced that it will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the potential of its Prospera Spinal Cord Stimulation (SCS) system.

1. FDA Clears GYDER Hip System
2. AdvaMed Seeking Medical Technology Exemption From Tariffs
3. Sounding Board: Looking Back at 2024 and Ahead to 2025
4. Evergen Launches AI-Powered Bone Graft Image Processing Software
5. BIOTRONIK Neuro Reveals Data from the BENEFIT-03 Clinical Study